Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California

Pharmacogenetics

Volumn 6, Issue 6, 1996, Pages 527-533

  London, Stephanie J ^a,b   Daly, Ann K ^c   Leathart, Julian B S ^c   Navidi, William C ^b   Idle, Jeffrey R ^c,d  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d Institute for Cancer Research   (Norway)

Author keywords

CYP2C9; cytochrome P450; genetic; susceptibility

Indexed keywords

BENZO[A]PYRENE; CYTOCHROME P450 ISOENZYME; DNA; WARFARIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CAUCASIAN; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; METABOLIC ACTIVATION; PRIORITY JOURNAL; RACE DIFFERENCE; UNITED STATES;

ADENOCARCINOMA; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BENZO(A)PYRENE; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; LOS ANGELES; LUNG NEOPLASMS; MIDDLE AGED; POLYMORPHISM, GENETIC; REFERENCE VALUES; RISK FACTORS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; VARIATION (GENETICS); WARFARIN;

EID: 0030468137     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199612000-00006     Document Type: Article

References (13)

1. Bauer E, Guo Z, Ueng Y, Bell LC, Zeldin D, Guengerich FP. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem Res Toxicol 1995: 8, 136-142.
2. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyes WA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 1996: 6, 193-201.
3. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995: 5, 389-392.
4. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as probe. Mol Pharmacol 1993: 43, 234-239.
5. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP, Kadlubar FF. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Env Health Perspect 1992: 85, 87-94.
6. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer Inst 1995: 87, 1246-1253.
7. 144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4, 39-42.
8. Shou M, Korzekwa KR, Crespi CL, Gonzalez FJ, Gelboin HV. The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Molecular Carcinogenesis 1994: 10, 159-168.
9. Sullivan TH, Ghanayem BI, Bell DA, Zhang Z, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamine polymorphism. Pharmacogenetics, 6, 000-000.
10. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO. Birkett DJ. Tolbutamine and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Comm 1991: 175, 1112-1118.
11. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP. Gasser R, Meyer UA, Birkett DJ. Site directed mutation studies of human liver cytochrome P-450 isozymes in the CYP2C subfamily. Biochem J 1993: 289, 533-538.
12. Yasumori T, Yamazoe Y, Kato R. Cytochrome P-450 human-s (P-450IIC9) in mephenytoin hydroxylation polymorphisms in human livers: Differences in substrate and stereoselectivities among microheterogeneous P-450IIC species expressed in yeasts. J Biochem 1991: 109, 711-711.
13. Zhong S, Wyllie AH, Barnes D, et al. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993: 14, 1821-4.